CRISPR Therapeutics AG (CRSP)

43.44 +0.30 (+0.68%) USD  |  NASDAQ  |  Mar 24, 16:00
43.35 -0.08 (-0.20%) After-Hours: 17:36
More
CRISPR Therapeutics Cash Flow
Export
December 2022 - March 2021
Last Period Last
Next Period
Prev Period
First Period First
Operations (Quarterly)
2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06 2021-03
Actual Release Date 02/21/2023 11/01/2022 08/08/2022 05/09/2022 02/21/2023 11/01/2022 08/08/2022 05/09/2022
Net Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Gain/Loss on Sale Business Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Foreign Currency Exchange Gain/Loss Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Pension and Employee Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Gain and Loss on Sale of PPE Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Gain (Loss) on Investment Securities Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Earnings Loss from Eq. Investments Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Gains Losses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Amortization Expense CF Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Depreciation Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Depreciation and Amortization Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Depreciation, Amortization, Depletion Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Deferred Taxes Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Amortization of Securities Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Asset Impairment Charge Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Unreali Gain/Loss Inv Q Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Stock Based Compensation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Excess Tax Benefit from Stock Compensation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Noncash Items Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Change in Receivables Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Change in Inventories Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Change in Prepaid Assets Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Change in Payables and Accrued Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Change in Other Current Assets Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Change in Other Current Liabilities Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Change in Other Working Cap Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Change in Taxes Payable Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Changes in Working Capital Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Cash from Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Cash from Operations -113.33M -105.22M -141.96M -135.24M -86.04M -81.33M 807.00M -100.66M
Investing (Quarterly)
2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06 2021-03
Actual Release Date 02/21/2023 11/01/2022 08/08/2022 05/09/2022 02/21/2023 11/01/2022 08/08/2022 05/09/2022
Net Change in Capital Expenditures Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Sale of PPE Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Change in PP&E Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Change in Intangibles Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Divestitures (Acquisitions) Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Net Change in Investments Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Other Investing Changes Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Cash from Investing -175.53M 87.46M -56.07M -114.52M -8.716M -565.18M -293.64M -167.90M
Financing (Quarterly)
2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06 2021-03
Actual Release Date 02/21/2023 11/01/2022 08/08/2022 05/09/2022 02/21/2023 11/01/2022 08/08/2022 05/09/2022
Net Change in Long Term Debt Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Change in Short Term Debt Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Debt Issuance Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Common Stock Issuance Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Common Stock Payments Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Common Equity Issued (Purchased) Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Preferred Stock Issuance Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Preferred Stock Payments Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Preferred Equity Issued (Purchased) Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Common Dividends Paid Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Preferred Dividends Paid Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Dividends Paid Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Proceeds from Stock Option Exercised Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Cash from Other Financing Activities Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Cash from Financing 2.478M 15.11M 10.35M 10.65M 6.299M 10.21M 8.443M 225.99M
Ending Cash (Quarterly)
2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06 2021-03
Actual Release Date 02/21/2023 11/01/2022 08/08/2022 05/09/2022 02/21/2023 11/01/2022 08/08/2022 05/09/2022
Beginning Cash Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Change in Cash Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Cash Foreign Exchange Adjustment Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Ending Cash Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Additional Items (Quarterly)
2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06 2021-03
Actual Release Date 02/21/2023 11/01/2022 08/08/2022 05/09/2022 02/21/2023 11/01/2022 08/08/2022 05/09/2022
Cash Disc Ops Adjust Q Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Issuance of Capital Stock Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Issuance of Debt Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Debt Repayment Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Repurchase of Capital Stock Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Stock Buybacks (Quarterly) 0.00 -0.97M 0.00 0.00 0.00 0.00 1.325M -214.59M
Income Tax Paid Supplemental Data Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Interest Paid Supplemental Data Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Domestic Sales Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Foreign Sales Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
SEC Filing Links
2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06 2021-03
As Originally Reported AOR AOR AOR AOR AOR AOR AOR AOR
Restated -- -- -- -- Restated Restated Restated Restated